Massachusetts General Hospital Diabetes Center and Harvard Medical School, Boston, MA, USA.
National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ, USA.
Diabetologia. 2019 Aug;62(8):1319-1328. doi: 10.1007/s00125-019-4928-8. Epub 2019 Jul 4.
The global epidemic of type 2 diabetes has prompted numerous studies and public health efforts to reduce its development. A variety of interventions, including lifestyle modifications and pharmacological agents directed at ameliorating the major risk factors for type 2 diabetes, are of proven efficacy in reducing the development of type 2 diabetes in people with impaired glucose tolerance. While prevention of the hyperglycaemia characteristic of diabetes is arguably an important, clinically relevant outcome, a more compelling outcome with greater clinical significance is the prevention or reduction of the relatively diabetes-specific microvascular and less-specific cardiovascular disease (CVD) complications associated with diabetes. These complications cause the majority of morbidity and excess mortality associated with diabetes. Any reduction in diabetes should, logically, also reduce the occurrence of its long-term complications; however, most diabetes prevention trials have not been of sufficient duration to allow such an evaluation. The limited long-term data, largely from the Da Qing Diabetes Prevention Study (DQDPS) and the Diabetes Prevention Program (DPP) and their respective follow-up studies (DQDPOS and DPPOS), suggest a reduction in microvascular complications and amelioration of CVD risk factors. Only the DQDPOS and Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) studies have shown a reduction in CVD events and only DQDPOS has demonstrated a decrease in CVD and overall mortality. While these limited data are promising, whether diabetes prevention directly reduces complication-related morbidity and mortality remains unclear. Longer follow-up of prevention studies is needed to supplement the limited current clinical trial data, to help differentiate the effects of diabetes prevention itself from the means used to reduce diabetes development and to understand the balance among benefits, risks and costs of prevention.
全球 2 型糖尿病流行促使人们开展了大量研究和公共卫生工作,以降低其发病率。各种干预措施,包括生活方式改变和针对 2 型糖尿病主要危险因素的药物治疗,已被证明可有效降低糖耐量受损人群 2 型糖尿病的发生。虽然预防糖尿病特征性高血糖可能是一个重要的、有临床意义的结果,但更具临床意义的、更引人注目的结果是预防或减少与糖尿病相关的相对糖尿病特异性微血管和非特异性心血管疾病(CVD)并发症。这些并发症导致了与糖尿病相关的大多数发病率和超额死亡率。任何减少糖尿病的措施,从逻辑上讲,也应该减少其长期并发症的发生;然而,大多数糖尿病预防试验的持续时间都不足以进行这种评估。有限的长期数据主要来自大庆糖尿病预防研究(DQDPS)和糖尿病预防计划(DPP)及其各自的随访研究(DQDPOS 和 DPPOS),表明微血管并发症减少和 CVD 危险因素改善。只有 DQDPOS 和预防非胰岛素依赖型糖尿病研究(STOP-NIDDM)显示 CVD 事件减少,只有 DQDPOS 显示 CVD 和总死亡率降低。虽然这些有限的数据很有希望,但糖尿病预防是否直接降低与并发症相关的发病率和死亡率仍不清楚。需要对预防研究进行更长时间的随访,以补充目前有限的临床试验数据,帮助区分糖尿病预防本身的效果与降低糖尿病发展所使用的手段,并了解预防的益处、风险和成本之间的平衡。